{
    "clinical_study": {
        "@rank": "142919", 
        "arm_group": [
            {
                "arm_group_label": "Single dose of VP 20629 or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Four groups of 8 subjects each will receive a single dose of VP 20629 (150 mg, 450 mg, 900 mg, or 1200 mg) or placebo."
            }, 
            {
                "arm_group_label": "Multiple doses of VP 20629 or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Three groups of 8 subjects each will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8."
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of the study are:\n\n        -  To evaluate the safety and tolerability of single and multiple oral doses of VP 20629\n           in subjects with Friedreich's ataxia (FA). [Primary]\n\n        -  To characterize the pharmacokinetics of VP 20629 by investigation of the plasma\n           concentration-time profile following single and multiple oral doses in subjects with\n           FA. [Secondary]\n\n        -  To investigate the pharmacodynamic effects of VP 20629 on plasma 8-isoprostane and\n           malondialdehyde and urinary 8-hydroxydeoxyguanosine concentrations following multiple\n           oral doses in subjects with FA. [Exploratory]"
        }, 
        "brief_title": "Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Friedreich's Ataxia", 
        "condition_browse": {
            "mesh_term": [
                "Ataxia", 
                "Friedreich Ataxia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Be 18 to 45 years of age (inclusive).\n\n          2. Have a body mass index between 18 and 27 kg/m^2 (inclusive).\n\n          3. Have a clinical presentation consistent with FA.\n\n          4. Have a confirmed diagnosis of FA with a defined expanded guanosine, adenine, adenine\n             (GAA) triplet repeat number.\n\n          5. Have an International Cooperative Ataxia Rating Scale (ICARS) mean total score of\n             \u226475.\n\n          6. If female, be postmenopausal (cessation of menses \u22651 year), surgically sterile, or\n             have a negative serum human chorionic gonadotropin pregnancy test within 5 days prior\n             to the first dose of study drug. Women of child bearing potential must also be on an\n             acceptable method of birth control, as determined by the Investigator, for 3 months\n             prior to the first dose and must agree to continue use through 2 months after the\n             last dose of study drug.\n\n             If male, be surgically sterile or agree to follow an acceptable method of birth\n             control as determined by the Investigator, from the screening visit through 2 months\n             after the last dose of study drug.\n\n          7. Be able to swallow capsules whole.\n\n          8. Agree to adhere to the protocol-defined schedule of assessments and procedures.\n\n          9. Be informed of the nature of the study and provide written informed consent before\n             any study-specific procedures are performed.\n\n        Exclusion Criteria:\n\n          1. Have taken coenzyme Q10, idebenone, other dietary or herbal supplements (with an\n             anti-oxidative effect), or over-the-counter medications (including homeopathic\n             medicines and vitamins) within 1 week prior to the first dose of study drug on Day 1.\n\n          2. If female, be pregnant or breastfeeding.\n\n          3. Have a positive test result for human immunodeficiency virus (HIV), hepatitis B\n             surface antigen, or hepatitis C antibody.\n\n          4. Have ingested any alcohol within 48 hours before admission to the clinical study unit\n             on Day -1. NOTE: Caffeine intake should be limited to 2 caffeine-containing beverages\n             per day during this same time period.\n\n          5. Have participated in an investigational drug trial within 30 days prior to the first\n             dose of study drug on Day 1. NOTE: Subjects who received study drug (VP 20629 or\n             placebo) in a single-dose group in this study and completed the Post-treatment Safety\n             Assessment are allowed to enroll in a multiple-dose group following a 21 day washout\n             period, provided they continue to meet protocol eligibility criteria. Subjects cannot\n             enroll in a multiple-dose group if they have an ongoing adverse event following\n             participation in a single-dose group or had a serious adverse event during a\n             single-dose group (regardless of causality).\n\n          6. Have a known hypersensitivity to any ingredient in the study formulation.\n\n          7. Have, as determined by the Investigator and/or medical monitor, any clinically\n             relevant medical or surgical condition that could interfere with the administration\n             of study drug, interpretation of study results, or compromise the safety or\n             well-being of the subject.\n\n          8. Have a Columbia-Suicide Severity Rating Scale (C-SSRS) score of 4 or 5."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898884", 
            "org_study_id": "20629-100"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Single dose of VP 20629 or placebo", 
                    "Multiple doses of VP 20629 or placebo"
                ], 
                "intervention_name": "VP 20629", 
                "intervention_type": "Drug", 
                "other_name": "Indole-3-propionic acid"
            }, 
            {
                "arm_group_label": [
                    "Single dose of VP 20629 or placebo", 
                    "Multiple doses of VP 20629 or placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "bclemente@mednet.ucla.edu", 
                    "last_name": "Brian Clemente", 
                    "phone": "310-794-1225"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "UCLA Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kbarber@health.usf.edu", 
                    "last_name": "Dr. Kelly Sullivan", 
                    "phone": "813-974-5909"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "University of South Florida"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rebecca.s.mcmurray@emory.edu", 
                    "last_name": "Rebecca McMurray", 
                    "phone": "404-728-6427"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Emory University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "carrie-stephan@uiowa.edu", 
                    "last_name": "Carrie Stephan", 
                    "phone": "319-356-2673"
                }, 
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa"
                    }, 
                    "name": "University of Iowa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "seyerl@email.chop.edu", 
                    "last_name": "Lauren Seyer", 
                    "phone": "267-426-9738"
                }, 
                "contact_backup": {
                    "email": "foerster@email.chop.edu", 
                    "last_name": "Debbie Foerster", 
                    "phone": "267-426-7584"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Children's Hospital of Philadelphia"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects With Friedreich's Ataxia", 
        "other_outcome": {
            "description": "Blood and urine samples will be collected to measure biomarkers of oxidative stress and damage in the multiple-dose groups. These markers are plasma 8-isoprostane and malondialdehyde and urinary 8-hydroxydeoxyguanosine.", 
            "measure": "Pharmacodynamic parameters", 
            "safety_issue": "No", 
            "time_frame": "10 days (multiple-dose groups only)"
        }, 
        "overall_official": {
            "affiliation": "ViroPharma", 
            "last_name": "Gwendolyn Niebler, DO", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events and clinically relevant changes in safety laboratory testing, vital signs, and 12-lead electrocardiograms", 
            "safety_issue": "Yes", 
            "time_frame": "10 days (single-dose groups) or 17 days (multiple-dose groups)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898884"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Blood and urine samples will be collected to assess the pharmacokinetics of VP 20629 and a potential metabolite in plasma and urine after single and multiple doses of VP 20629.", 
            "measure": "Pharmacokinetic parameters (e.g., Cmax, Tmax, AUC, t1/2)", 
            "safety_issue": "No", 
            "time_frame": "3 days (single-dose groups) or 10 days (multiple-dose groups)"
        }, 
        "source": "Shire", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shire", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}